Dr. Christopher R. Henry, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Medical College of Wisconsin (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 625
Licensed in Texas since 2015, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Medical College of Wisconsin
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
TX license Q5426 (first issued 2015; active) -
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
TX license Q5426 (first issued 2015; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Retina Consultants of Houston PLLC (25 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 625
- Services billed
- 12,596
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, aflibercept, 1 mg | 2,320 | 201 |
| Imaging of retina | 1,954 | 604 |
| Injection, ranibizumab, 0.1 mg | 1,563 | 42 |
| Injection of drug into eye | 1,231 | 277 |
| Established patient complete exam of visual system | 1,138 | 530 |
| Injection, dexamethasone, intravitreal implant, 0.1 mg | 154 | 11 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 104 | 11 |
| Photography of the retina | 101 | 84 |
| Established patient office or other outpatient visit, 30-39 minutes | 95 | 70 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 63 | 54 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Houston, TX | 207 |
| Latanoprost Other prescribers in Houston, TX | 136 |
| Brimonidine Tartrate Other prescribers in Houston, TX | 113 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Houston, TX | 93 |
| Prednisone Other prescribers in Houston, TX | 70 |
| Dorzolamide Hcl Other prescribers in Houston, TX | 61 |
| Timolol Maleate Other prescribers in Houston, TX | 47 |
| Difluprednate | 45 |
| Bromfenac Sodium | 43 |
| Atropine Sulfate | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 38 payments worth $10,574 in total to this clinician.
| Genentech USA, Inc. | $8,672 |
|---|---|
| Penumbra, Inc. | $573 |
| Bausch & Lomb Americas Inc. | $546 |
| Astellas Pharma US Inc | $188 |
| Regeneron Healthcare Solutions, Inc. | $176 |
| AbbVie Inc. | $164 |
| Apellis Pharmaceuticals, Inc. | $159 |
| Amgen Inc. | $41.21 |
| Consulting Fee | $7,575 |
|---|---|
| Travel and Lodging | $1,384 |
| Food and Beverage | $1,114 |
| Speaking at a medical education program | $500 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Nov 15, 2025 | Consulting Fee | $7,575 |
| Penumbra, Inc. Nov 19, 2025 | Travel and Lodging Indigo System · Peripheral Intervention · travel to San Francisco, CA | $573 |
| Bausch & Lomb Americas Inc. Jul 17, 2025 | Speaking at a medical education program XIPERE · Ophthalmology | $500 |
| Genentech USA, Inc. Nov 15, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $394 |
| Genentech USA, Inc. Nov 15, 2025 | Travel and Lodging travel to San Francisco, CA · in-kind | $231 |
| Genentech USA, Inc. Nov 15, 2025 | Travel and Lodging travel to San Francisco, CA | $186 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $59,930 in research payments for these studies, mostly to the institutions running them.
- A phase iii study to investigate RO7200220 in patients with uveitic macular edema
Genentech, Inc. - Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Ani Pharmaceuticals, Inc. · Status unknown · NCT05322070
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.